Favrille, Inc. (Nasdaq: FVRL) has entered into an agreement with Berlex, Inc. (996344) in order to study the use of Favrille's active immunotherapy, FavId® (Id/KLH), in combination with Berlex's growth factor Leukine® (sargramostim, GM-CSF) in patients with B-cell non-Hodgkin's lymphoma (NHL).
FavId® is a patient-specific, Id/KLH, active immunotherapy for the treatment of NHL currently undergoing Phase 3 clinical trial, while Leukine® is a recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) - a growth factor that is currently used to help fight infections in appropriate patients by enhancing immune cell function.
Favrille is a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer and Berlex, Inc. is a U.S. affiliate of Bayer Schering Pharma AG, Germany (OTC: SHRGY)
The terms of agreement were not disclosed.
Find more details from the press release.
Comment Preview